共 129 条
[1]
Torre LA(2015)Global cancer statistics, 2012 CA Cancer J Clin 65 87-108
[2]
Bray F(2012)Controversies and challenges regarding the impact of radiation therapy on survival Ann Oncol 00 1-9
[3]
Siegel RL(2017)Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer N Engl J Med 377 1919-1929
[4]
Chargari C(2010)Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non–small-cell lung cancer J Clin Oncol 28 2181-2190
[5]
Soria JC(2007)Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non–small-cell lung cancer: Cancer and Leukemia Group B J Clin Oncol 25 1698-1704
[6]
Deutsch E(2005)Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol J Clin Oncol 23 5883-5891
[7]
Antonia SJ(2008)Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S.Oncology J Clin Oncol 26 5755-5760
[8]
Villegas A(2012)Updated survival and outcomes for older adults with inoperable stage III non-small-cell lung cancer treated with cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel: analysis of a phase III trial from the Hoosier Oncology Group (HOG) and US Oncology Ann Oncol 23 1730-1738
[9]
Daniel D(2016)Cancer treatment and survivorship statistics, 2016 CA Cancer J Clin 66 271-289
[10]
Vicente D(2010)Elective nodal irradiation (ENI) vs. involved field radiotherapy (IFRT) for locally advanced non-small cell lung cancer (NSCLC): a comparative analysis of toxicities and clinical outcomes Radiother Oncol 95 178-184